Ubenimex synergizes with the PD-L1 blockade in gastric cancer by competitively binding LAP3 with UBE3A

Qin N, Fan Y, Yang T, Yang Z, Fan D. The burden of Gastric Cancer and possible risk factors from 1990 to 2021, and projections until 2035: findings from the Global Burden of Disease Study 2021. Biomark Res. 2025;13:5.

Google Scholar 

Kornepati AVR, Vadlamudi RK, Curiel TJ. Programmed death ligand 1 signals in cancer cells. Nat Rev Cancer. 2022;22:174–89.

Google Scholar 

Janjigian YY, Kawazoe A, Bai Y, Xu J, Lonardi S, Metges JP, et al. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial. Lancet. 2023;402:2197–208.

Google Scholar 

Shen L, Zhang Y, Li Z, Zhang X, Gao X, Liu B, et al. First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial. Nat Med. 2025;31:1163–70.

Google Scholar 

Mestrallet G, Brown M, Bozkus CC, Bhardwaj N. Immune escape and resistance to immunotherapy in mismatch repair deficient tumors. Front Immunol. 2023;14:1210164.

Google Scholar 

Yu Y. Multi-target combinatory strategy to overcome tumor immune escape. Front Med. 2022;16:208–15.

Google Scholar 

Luo D, Zhou J, Ruan S, Zhang B, Zhu H, Que Y, et al. Overcoming immunotherapy resistance in gastric cancer: insights into mechanisms and emerging strategies. Cell Death Dis. 2025;16:75.

Google Scholar 

Vesely MD, Zhang T, Chen L. Resistance Mechanisms to Anti-PD Cancer Immunotherapy. Annu Rev Immunol. 2022;40:45–74.

Google Scholar 

Galassi C, Chan TA, Vitale I, Galluzzi L. The hallmarks of cancer immune evasion. Cancer Cell. 2024;42:1825–63.

Google Scholar 

Yuan Y, Adam A, Zhao C, Chen H. Recent Advancements in the Mechanisms Underlying Resistance to PD-1/PD-L1 Blockade Immunotherapy. Cancers. 2021;13:663.

Google Scholar 

Wang F, Jin Y, Wang M, Luo HY, Fang WJ, Wang YN, et al. Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS/pMMR colorectal cancer: a randomized phase 2 trial. Nat Med. 2024;30:1035–43.

Google Scholar 

Okabe S, Tanaka Y, Gotoh A. Targeting phosphoinositide 3-kinases and histone deacetylases in multiple myeloma. Exp Hematol Oncol. 2021;10:19.

Google Scholar 

Shi MQ, Xu Y, Fu X, Pan DS, Lu XP, Xiao Y, et al. Advances in targeting histone deacetylase for treatment of solid tumors. J Hematol Oncol. 2024;17:37.

Google Scholar 

Shen C, Li M, Duan Y, Jiang X, Hou X, Xue F, et al. HDAC inhibitors enhance the anti-tumor effect of immunotherapies in hepatocellular carcinoma. Front Immunol. 2023;14:1170207.

Google Scholar 

Sekine K, Fujii H, Abe F. Induction of apoptosis by bestatin (ubenimex) in human leukemic cell lines. Leukemia. 1999;13:729–34.

Google Scholar 

Piedfer M, Dauzonne D, Tang R, N’Guyen J, Billard C, Bauvois B. Aminopeptidase-N/CD13 is a potential proapoptotic target in human myeloid tumor cells. FASEB J. 2011;25:2831–42.

Google Scholar 

Liu X, Guo Q, Jing F, Zhou C, Xiu T, Shi Y, et al. Ubenimex Suppresses the Ability of Migration and Invasion in Gastric Cancer Cells by Alleviating the Activity of the CD13/NAB1/MAPK Pathway. Cancer Manag Res. 2021;13:4483–95.

Google Scholar 

Shi Y, Guo Q, Jing F, Shang X, Zhou C, Jing F. Ubenimex suppresses glycolysis mediated by CD13/Hedgehog signaling to enhance the effect of cisplatin in liver cancer. Transl Cancer Res. 2023;12:2823–36.

Google Scholar 

Hu X, Xiong H, Huang S, Mao T, Yang L, Su T. Efficacy of Standardised Treatments Combined with Ubenimex in Patients with Malignant Tumors. J Coll Phys Surg Pak. 2021;31:206–9.

Google Scholar 

Iwahashi M, Tanimura H, Yamaue H, Tani M, Noguchi K, Mizobata S, et al. Ubenimex treatment enhances the susceptibility of gastric cancer cell lines to lymphokine-activated killer cells. Anticancer Res. 1994;14:1563–8.

Google Scholar 

Ota K, Kurita S, Yamada K, Masaoka T, Uzuka Y, Ogawa N. Immunotherapy with bestatin for acute nonlymphocytic leukemia in adults. Cancer Immunol Immunother. 1986;23:5–10.

Google Scholar 

Matsui M, Fowler JH, Walling LL. Leucine aminopeptidases: diversity in structure and function. Biol Chem. 2006;387:1535–44.

Google Scholar 

Ishizaki T, Tosaka A, Nara T, Aoshima N, Namekawa S, Watanabe K, et al. Leucine aminopeptidase during meiotic development. Eur J Biochem. 2002;269:826–32.

Google Scholar 

Feng L, Chen Y, Xu K, Li Y, Riaz F, Lu K, et al. Cholesterol-induced leucine aminopeptidase 3 (LAP3) upregulation inhibits cell autophagy in pathogenesis of NAFLD. Aging. 2022;14:3259–75.

Google Scholar 

He X, Huang Q, Qiu X, Liu X, Sun G, Guo J, et al. LAP3 promotes glioma progression by regulating proliferation, migration and invasion of glioma cells. Int J Biol Macromol. 2015;72:1081–9.

Google Scholar 

Fang C, Zhang J, Yang H, Peng L, Wang K, Wang Y, et al. Leucine aminopeptidase 3 promotes migration and invasion of breast cancer cells through upregulation of fascin and matrix metalloproteinases-2/9 expression. J Cell Biochem. 2019;120:3611–20.

Google Scholar 

Wang X, Shi L, Deng Y, Qu M, Mao S, Xu L, et al. Inhibition of leucine aminopeptidase 3 suppresses invasion of ovarian cancer cells through down-regulation of fascin and MMP-2/9. Eur J Pharm. 2015;768:116–22.

Google Scholar 

Zhang S, Yang X, Shi H, Li M, Xue Q, Ren H, et al. Overexpression of leucine aminopeptidase 3 contributes to malignant development of human esophageal squamous cell carcinoma. J Mol Histol. 2014;45:283–92.

Google Scholar 

Li L, Li F, Hu X, Wu Z, Ren W, Wang T, et al. LAP3 contributes to IFN-γ-induced arginine depletion and malignant transformation of bovine mammary epithelial cells. BMC Cancer. 2022;22:864.

Google Scholar 

Li W, Xiang S, Zeng H. LAP3 regulation of MMP-2/9 expression on invasion and metastasis of human skin malignant melanoma cells. Labeled Immunoass Clin Med. 2021;28:1222–34.

Google Scholar 

Tian SY, Chen SH, Shao BF, Cai HY, Zhou Y, Zhou YL, et al. Expression of leucine aminopeptidase 3 (LAP3) correlates with prognosis and malignant development of human hepatocellular carcinoma (HCC). Int J Clin Exp Pathol. 2014;7:3752–62.

Google Scholar 

Wu J, Li L, Zhang H, Zhao Y, Zhang H, Wu S, et al. A risk model developed based on tumor microenvironment predicts overall survival and associates with tumor immunity of patients with lung adenocarcinoma. Oncogene. 2021;40:4413–24.

Google Scholar 

MacArthur Clark JA, Sun D. Guidelines for the ethical review of laboratory animal welfare People’s Republic of China National Standard GB/T 35892-2018 [Issued 6 February 2018 Effective from 1 September 2018]. Anim Model Exp Med. 2020;3:103–13.

Google Scholar 

Grasselly C, Denis M, Bourguignon A, Talhi N, Mathe D, Tourette A, et al. The Antitumor Activity of Combinations of Cytotoxic Chemotherapy and Immune Checkpoint Inhibitors Is Model-Dependent. Front Immunol. 2018;9:2100.

Google Scholar 

Stathopoulou C, Gangaplara A, Mallett G, Flomerfelt FA, Liniany LP, Knight D, et al. PD-1 Inhibitory Receptor Downregulates Asparaginyl Endopeptidase and Maintains Foxp3 Transcription Factor Stability in Induced Regulatory T Cells. Immunity. 2018;49:247–63.

Google Scholar 

Cheng Q, Zuo X, Wang Z, Lu W, Jiang Y, Liu J, et al. Intrapleural dual blockade of IL-6 and PD-L1 reprograms CAF dynamics and the tumor microenvironment in lung cancer-associated malignant pleural effusion. Respir Res. 2025;26:180.

Google Scholar 

Bauvois B, Dauzonne D. Aminopeptidase-N/CD13 (EC 3.4.11.2) inhibitors: chemistry, biological evaluations, and therapeutic prospects. Med Res Rev. 2006;26:88–130.

Google Scholar 

Nakamichi S, Kubota K, Matsuyama K, Misumi T, Kozuki T, Sugawara S, et al. A Phase Ⅱ Study of Ubenimex Combined With Pembrolizumab, Nab-Paclitaxel, and Carboplatin for Previously Untreated Advanced Squamous Non-Small-Cell Lung Cancer: TORG2241 (UBE-Q). Clin Lung Cancer. 2024;25:85–90.

Google Scholar 

Zhou H, Jing S, Liu Y, Wang X, Duan X, Xiong W, et al. Identifying the key genes of Epstein-Barr virus-regulated tumour immune microenvironment of gastric carcinomas. Cell Prolif. 2023;56:e13373.

Google Scholar 

Baer R, Bankier AT, Biggin MD, Deininger PL, Farrell PJ, Gibson TJ, et al. DNA sequence and expression of the B95-8 Epstein-Barr virus genome. Nature. 1984;310:207–11.

Google Scholar 

Jo H, Shin CM. Infectious Gastric Diseases Other than Helicobacter. Korean J Gastroenterol. 2023;82:269–81.

Google Scholar 

Song HJ, Kim KM. Pathology of Epstein-Barr Virus-Associated Gastric Carcinoma and Its Relationship to Prognosis. Gut Liver. 2011;5:143–8.

Google Scholar 

Cui Y, Liu J, Wang X, Wu Y, Chang Y, Hu X, et al. Baicalin attenuates the immune escape of oral squamous cell carcinoma by reducing lactate accumulation in tumor microenvironment. J Adv Res. 2025;77:721–32.

Google Scholar 

Arora M, Kundu A, Sinha S, Chosdol K. Immune factors and their role in tumor aggressiveness in glioblastoma: Atypical cadherin FAT1 as a promising target for combating immune evasion. Cell Mol Biol Lett. 2025;30:89.

Google Scholar 

Martinkova L, Zatloukalova P, Kucerikova M, Friedlova N, Tylichova Z, Zavadil-Kokas F, et al. Inverse correlation between TP53 gene status and PD-L1 protein levels in a melanoma cell model depends on an IRF1/SOX10 regulatory axis. Cell Mol Biol Lett. 2024;29:117.

Google Scholar 

Shalaby KE, Abdelalim EM. Hypoimmune stem cells and islets: hype or a true breakthrough in diabetes treatment? Cell Mol Biol Lett. 2025;30:112.

Google Scholar 

Ma X, Jia S, Wang G, Liang M, Guo T, Du H, et al. TRIM28 promotes the escape of gastric cancer cells from immune surveillance by increasing PD-L1 abundance. Signal Transduct Target Ther. 2023;8:246.

Google Scholar 

Gao Y, Nihira NT, Bu X, Chu C, Zhang J, Kolodziejczyk A, et al. Acetylation-dependent regulation of PD-L1 nuclear translocation dictates the efficacy of anti-PD-1 immunotherapy. Nat Cell Biol. 2020;22:1064–75.

Google Scholar 

Wu Y, Zhang C, Liu X, He Z, Shan B, Zeng Q, et al. ARIH1 signaling promotes anti-tumor immunity by targeting PD-L1 for proteasomal degradation. Nat Commun. 2021;12:2346.

Google Scholar 

Shi C, Wang Y, Wu M, Chen Y, Liu F, Shen Z, et al. Promoting anti-tumor immunity by targeting TMUB1 to modulate PD-L1 polyubiquitination and glycosylation. Nat Commun. 2022;13:6951.

Google Scholar 

Miao Z, Li J, Wang Y, Shi M, Gu X, Zhang X, et al. Hsa_circ_0136666 stimulates gastric cancer progression and tumor immune escape by regulating the miR-375/PRKDC Axis and PD-L1 phosphorylation. Mol Cancer. 2023;22:205.

Google Scholar 

Zhang S, Wang HY, Tao X, Chen Z, Levental I, Lin X. Palmitoylation of PD-L1 Regulates Its Membrane Orientation and Immune Evasion. Langmuir. 2025;41:5170–8.

Google Scholar 

Singh S, Sivaraman J. Crystal structure of HECT domain of UBE3C E3 ligase and its ubiquitination activity. Biochem J. 2020;477:905–23.

Google Scholar